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Three carcinoma-associated oncogenes, two of which have
been strongly implicated in human mammary tumorigenesis,
have been introduced into a novel mouse mammary epithelial
cell line, EF43, that retains many differentiated functions.
The effect of oncogene expression upon classical transform-
ation parameters as well as parameters specific for mammary
epithelial cells such as growth in three-dimensional collagen
matrices and the ability to repopulate the cleared mammary
fat pad and to form alveolar structures in vivo has been
investigated. Expression of \-myc in EF43 cells results in no
obvious phenotypk changes, and does not confer tumorigenic
potential upon the cells. Expression of v-Ha-ras confers upon
EF43 cells the ability to grow rapidly, grow in an anchorage-
independent manner, results in tumor formation in nude and
syngeneic animals, abolishes their ability to repopulate the
mammary gland and, instead, results in rapid induction of
anaplastic tumors. The v-mil oncogene, an avian homolog of
the mouse \-mht and human c-raf oncogenes, previously
thought to be non-transforming in the absence of a co-
operating oncogene, transforms EF43 cells, allowing them to
grow in an anchorage-independent manner, form tumors in
nude mice and abolishes their ability to repopulate the cleared
mammary fat pad. In contrast to v-ras, however, the tumors
arising from \-mil expression have a differentiated morphology,
typical of adenocarcinomas. Thus, different oncogenes show
varying degrees of inhibition of the differentiation of mammary
epithelial cells in vivo.
Introduction
Neoplastic transformation of the mammary gland proceeds via
a multistep pathway involving the tumorigenic conversion of one
or a number of mammary cell types. The identity of the cell types
involved in this process, their interaction during the conversion
and the identity of the cellular genes which are deregulated is
open both to speculation and investigation.
Transfection of DNA from the human mammary tumor derived
cell line MCF-7 into NIH/3T3 fibroblasts has identified potential
mammary oncogenes (1). Additionally, the Ha-ras oncogene has
been found activated or overexpressed in some human mammary
•Abbreviations: EGF, epidermal growth factor, HANs, hyperplastic alveolar
nodules.
tumors (2 -4 ) and a human mammary tumor cell line (5,6). Two
erb-B related genes, the human epidermal growth factor (EGF*)
receptor gene (7,8) and the neu oncogene (9) have been
found amplified in human mammary carcinoma derived cell lines.
More recently, the neu oncogene has been shown to be amplified
in primary mammary tumors (10). Similarly, the c-myc gene has
been found to be amplified (11) and overexpressed in some human
primary breast carcinomas (12).
In the mouse, depending upon strain, either plaques or hyper-
plastic alveolar nodules (HANs) represent the first visible
preneoplastic lesion. HANs, and less frequently plaques, may
eventually progress to overt mammary tumors (13). During this
progression a number of genes may become activated including
the putative mammary oncogenes, int-1 (14), int-2 (15), int-3
(16) and int-H (17). Two of these oncogenes have been shown
to be activated early in mammary tumorigenesis (18,19).
Although there is a correlation between expression of
oncogenes and the transformed phenotype, a causal relationship
between expression and transformation of the normal mammary
gland has not yet been demonstrated. In order to determine
whether any of the known oncogenes implicated in mammary
tumorigenesis are causally involved, we have introduced the
activated cellular Ha-ras oncogene, the viral ras and myc
oncogenes, and the v-mil oncogene—the murine homolog of
which has been implicated in carcinoma formation (20,21)—into
a normal mouse mammary epithelial cell line, EF43. Although
this mammary cell line is able to divide indefinitely in culture,
it retains many of the properties of normal mammary epithelial
cells, including the ability to repopulate the cleared mammary
fat pad and respond to the mammotropic stimuli of pituitary
hormones.
The effects of the expression of these genes on classical
parameters of transformation such as morphology, anchorage-
independent growth and tumorigenicity in nude and syngeneic
mice have been investigated. In addition, we have examined the
consequences of the expression of these oncogenes upon some
properties of differentiated mammary epithelial cells such as the
ability to grow in collagen matrices, induction of casein in
response to treatment with lactogenic hormones, and repopulation
of cleared mammary fat pads. Finally we determined the effects
of these oncogenes on the dependence of mammary epithelial
cells upon EGF, insulin and serum for growth.
Our data suggest that the introduction and expression of the
activated c-Ua-ras or v-Ha-ras and the \-mil oncogene in normal
mouse mammary epithelial cells results in tumorigenic conversion
and interference with the in vivo differentiation of the cells. In
contrast, expression of the v-myc gene in these cells does not
appear to interfere with normal mammary differentiation in terms
of the parameters we have measured.
Materials and methods
Plasmid vectors
A 1.7-kb BamHl-BglU fragment containing the v-Ha-raj gene from Harvey
murine sarcoma virus (pHaSV; 22) and a 1.5-kb BamHl -Aval fragment containing
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Fig. 1. Schematic diagrams of the plasmids pMMCV-neo (26), pZIPras and
pZIPmiJ. pZIPras and pZIPmil were constructed as outlined in Materials
and methods. flamHI sites are designated B, BglQ sites are designated Bg,
Aval sites are designated A, Clal sites are designated C. The herpes simplex
thymidine kinase promoter is marked titf* and the direction of the promoter
is indicated by open arrows. The neomycin-resistance gene from Ta5 is
marked neor. The tetracycline- and ampicillin-resistance genes are indicated
Tc* and Ar/ respectively. Direction of gene transcription is indicated by
closed arrows.
the v-mil gene of the MH-2 virus (pMH-2-BH; 23) were inserted in the syn
orientation into the flamHI site of pZIPneoSV(X) (24) to generate the plasmids
pZIP-ras and pTJP-mil respectively (Figure 1A and B). The \-myc containing
pMMCV-neo plasmid (Figure 1C; 25) was kindly provided by B.Vennstrom,
Heidelberg, FRG. The pSV2neo-FJ plasmid was derived from pSV2-neo (26)
by the insertion of a 6.6-kb flamHI fragment of cloned genomic DNA from the
plasmid pEJ (27) into the unique BamHI site of pSV2-neo (N.E.Hynes, Ludwig
Institute, Bern, unpublished).
Cell culture, transfections and retroviral infections
EF43 cells were cultured in DMEM supplemented with 10% fetal bovine serum,
1% penicillin/streptomycin; 1 /ig/ml insulin and 5 ng/ml EGF. Cells were
transfected with the plasmid pSV2neo-EJ essentially as outlined previously (28).
Stable, neomycin-resistant clones were selected in 200 fig/ml G418. Retroviral
infection after transient transfection of *2 cells (29) was carried out as described
previously (30).
Test for growth factor dependence
Suspensions of single cells at a density of 1 x 104 were seeded in a 6-cm plate
in normal medium. The medium was changed 24 h later to medium containing
combinations of 0.5% fetal serum, EGF and insulin. Duplicate cultures were
counted in a Coulter Counter at this time and 6 days later.
Growth in collagen
Cells were established in collagen matrix cultures essentially as described by Jones
and Hosick (31). Briefly, 1 x 105 cells were resuspended in 10 1^ of medium
and mixed with 80 /ii of rat-tail collagen (1 mg/ml, 6 jd/ml 6.27 mM acetic acid)
and 10 ul setting solution (6 x RPMI, 0.075 N NaOH, 0.0245 g/ml NaHCOj).
This mixture was plated into a collagen-coated well of a 12-well cluster plate
and left to set 15 min at 37°C. Two milliliters of medium were then added to
each well, the collagen matrices detached from the Petri dish and the collagen
cultures incubated for 2 - 4 weeks under normal conditions with regular medium
changes.
Assay for growth in soft agar
Cells (1 x 105) from a single cell suspension were plated into 8 ml of DMEM
containing antibiotics, 10% fetal calf serum and 0.35% bacto-agar. This was
layered into 6-cm Pern dishes precoated with a bottom layer of 2 x soft agar.
The soft agar dishes were incubated in moist chambers under normal culture
conditions. The appearance of colonies of cells growing in the soft agar was noted
after 2 weeks.
Assay for tumorigenidty in nude mice
Cells (1 x 106) from a single cell suspension were washed twice in serum- and
pyrogen-frec DMEM before being resuspended in 200 /il of the same medium.
This was injected s.c. into 2-week-old Nu/Nu mice under aseptic conditions. The
mice were observed once a week for the appearance of tumors at the site of
injection.
Repopulation of the cleared mammary fat pad
Cells ( 1 - 3 x 105) in serum-free Hanks' medium were injected in a 10-^ 1
volume into the cleared no.4 fat pads of 18-day-old female BALB/c mice using
a 30-gauge Hamilton Syringe (32).
Pituitary isograft procedure
Pituitary isografts were performed using the method of rcf. 33. Pituitary donors
were killed by cervical dislocation, the pituitary gland removed and inserted into
an 18-gauge trocar. Two pituitaries were inserted into the spleen of anesthetized
recipient mice. The hormonal activity of the isografts was assessed by evaluating
vaginal smears and by microscopic examination of the isograft and mammary
glands.
Preparation of whole amounts of mammary fat pads
After ventral incision, the no. 4 mammary glands were removed with the skin
flap attached and fixed in acetic acid/ethanol (1:3 v/v) for at least 1 h. The glands
were washed in 70% ethanol and then in distilled water before being dissected
away from skin. The glands were stained in Alum Carmine solution for at least
4 h, washed with ethanol and then destained in methyl salicylate.
Expression of oncogene products
To test for expression of p21"" in the EF43J series and in EF43zip-ras-oop, cell
membrane preparations were made as outlined previously (30). The proteins were
separated on a 17% SDS-polyacrylamide gel, electroblotted to nitrocellulose
and reacted with the appropriate antisera and visualized as previously described
(30). AMi-p2\"" was kindly donated by Dr R.Sweet (Smith, Kline and French
Laboratories, Philadelphia, PA). Radiolabeling of cellular protein with [35S]-
methionine, extraction and immunoprecipitation of the v-myc and v-mil proteins
was performed as outlined previously (28) using anti-mvc serum (Cambridge
Research Biochemicals) and anti-mi'/ serum, kindly supplied by J.Ghysdael (Institut
Pasteur, Lille, France).
Results
Characterization of EF43 cells
The mammary epithelial cell line EF43 was derived as a clonal
outgrowth from the mammary gland of an irradiated BALB/c
female mouse as previously described (34). EF43 cells retain most
of the differentiation characteristics of normal mammary
epithelium including the formation of normal ductal structures
in the cleared mammary fat pads of syngeneic mice (Figure 4A).
Further, when these mice receive pituitary isografts, the ductal
structures form alveolar outgrowths at a frequency of 60%
(Figure 4A, inset), demonstrating that EF43 cells are capable
of responding to the mammotropic effects of pituitary hormones.
EF43-derived outgrowths differentiate in pregnant mice and
produce milk, regressing to normal ductal structures following
weaning of the litter. The EF43 cell line is heterogeneous with
respect to keratin expression using the DAKO rabbit anti-human
stratum corneum keratin antiserum (results not shown).
Heterogeneity in keratin expression has been reported for another
mouse mammary cell line that produces mammary outgrowths
(35). Taken together, these data suggest that EF43 cells may be
mammary progenitor cells.
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Fig. 2. Expression of the raj, miV and myc oncogene proteins. (A) Membrane proteins from EF43 cells (lane 2), EF43 cells infected with ZIPras virus (lane
1) and five clones of EF43 cells transfected with pSV2neo-EJ, Jl (tone 3); J2 (lane 4); J3 (lane 5); J6 (lane 6); and J7 (tone 7) were separated on a 14%
SDS-polyacrylamidc-gel. After transfer to nitrocellulose, raj-specific proteins were visualized by treatment of the filter with anti-p21ral followed by incubation
with iodinated protein A. The p21"" protein is marked. (B) EF43 cells infected with ZIPneoSV(X) (lanes 1 and 3), TJP-rnU (lane 2) or TSP-myc (tone 4)
virus were cultured in DMEM with 10~5 M methionine plus 200 /xCi [35S]methionine for 3 h. Total cell proteins were extracted and immunoprecipitated with
anti-miZ (lanes 1 and 2) or anti-wye (lanes 3 and 4) serum. The anti-ra7 serum specifically precipitates a protein of 48 led. The anti-myc serum specifically
precipitates p57myc. The positions of reference standard proteins are marked.
Introduction and expression of the oncogenes ras, myc and
mil in the EF43 mammary cell line
The plasmid pSV2neo-EJ containing the activated c-Ha-ras gene
and the gene for neomycin resistance was transfected into the
EF43 cell line. G418-resistant clones were selected and grown
into mass culture for Southern blot analysis. Five cell clones (Jl,
J2, J3, J6 and J7) contained the transfected plasmid and were
chosen for further analysis (data not shown).
Retroviral infection has become an attractive method for the
introduction of genes into cells (for review see 36). Among the
reasons for this are the relatively high efficiency of gene transfer
as well as the stability, integrity and low copy number of the
acquired proviral DNA. Infection of EF43 cells with virus
produced upon transfection of the ¥2 MoMLV packaging cell
line (29) with pZTPneoSV(X) proceeds with high efficiency (30;
N.B. EF43 is referred to as #43). We therefore sought to use
retroviral vectors as an efficient means of introducing oncogenes
into the EF43 cell line.
The pZIPneoSV(X), pZIPras, pZiPmil and v-wyc-containing
pMMCV-neo plasmids (Figure 1) were independently transfected
into the ¥2 MoMLV packaging cell line (29) and the virus
produced used to infect EF43 cells. G418-resistant populations
of EF43 cells independently infected with ras-containing virus
(EF43zip-ro$-pop), the mi/-containing virus (EF43zip-mi/-pop),
and the empty ZIPneoSV(X) vector (EF43zip-pop) were estab-
lished. In addition, a clone of EF43 cells infected with myc-
containing virus (EF43myc) was obtained. Southern blot analysis
of the infected EF43 cell populations showed that each has
acquired the appropriate viral DNA (data not shown).
Expression of introduced oncogenes in EF43 cells
Expression of the ras oncogene in the pSV2neo-EJ-transfected
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Fig. 3. Graphic representation of growth factor dependence of EF43 cells.
The rate of growth from duplicate points of cells grown logarithmically over
a period of 6 days was determined in medium containing (A) 0.5% fetal
calf serum, 1 jjg/ml insulin and 5 ng/ml EGF; (B) 0.5% fetal calf serum
and 5 ng/ml EGF; (C) 0.5% fetal calf serum and 1 ^g/ml insulin; (D) 0.5%
fetal calf serum; (E) 5 ng/ml EGF and 1 /ig/ml insulin. Growth rate of
EF43 cells infected with the ZlPneoSV(X) virus is shown by open blocks,
of EF43 cells infected with the TSP-ras virus, EF43ap-rai-pop, by
descending shading (left to right) and of EF43 cells infected by the TJP-mil
virus, EF43zip-m7-pop, by ascending shading (left to right). The error bars
indicate the deviation of the actual data from the plotted mean.
EF43 cell lines and the ZIP-ray-infected EF43 cell population
was analysed by Western blotting of crude membrane extracts
(Figure 2A). Little if any p21rai is detected in the EF43 cell line
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(lane 2). Relatively high levels of p21"" are detectable in both
the virus-infected EF43zip-r<z?-pop (lane 1), and the five
pSV2neo-EJ-transfected cell clones J2 (lane 4), J6 (lane 6) and
J7 (lane 7) and lower levels in cell clones Jl (lane 3) and J3 Qane
5). The expression of the mil and myc proteins was investigated
by immunoprecipitation. A mi/-specific protein of 48 kd is detec-
ted in the ZIP-m//-infected population of EF43 cells (Figure 2B,
lane 2) which is not present in control ZIPneoSV(X) virus-infec-
ted cells (Figure 2B, lane 1) or non-infected EF43 cells (data not
shown). This protein is smaller than that seen in MH2 virus-
infected cells (plOO) presumably since it lacks the fused gag-
specific sequences (37). A similar ra/-related protein of 48 kd
has been previously described (38). Expression of the myc gene
in the MMCV-neo virus-infected cell line EF43-wyc was also
investigated. Using anu-myc serum, p57mK is detectable in
EF43-m;yc cells (Figure 2B, lane 4) but not in ZIPneoSV(X)
virus-infected EF43 cells (Figure 2B, lane 3). The endogenous
c-myc protein is expressed at very low levels and is undetectable
in this experiment. Expression of pS?"^ in the EF43-OTVC cells
was also demonstrated by Western blotting (data not shown).
Thus, expression of the introduced oncogenes can be detected
in each of the ras-, mil- and wye-infected cell lines.
Effect of oncogene expression upon growth of the EF43 cell
line
Oncogenes are known to alleviate dependence upon growth
factors (for reviews see 39,40). We therefore sought to investigate
the effects of expression of oncogenes upon growth factor
dependence of the EF43 cell line. To eliminate any effects of
clonal variation we compared only the TXP-ras and TJP-mil virus-
infected populations with the ZIPneo SV(X) virus-infected EF43
cell line. The rate of growth of logarithmically growing control
EF43zipSV(X) cells and EF43zip-ray- and EF43zip-/w7-infected
populations was determined over a 6-day period. EF43 cells grow
in the presence of 0.5% fetal bovine serum supplemented with
either EGF or insulin or both (Figure 3). In the absence of both
EGF and insulin, the growth rate of the EF43 cells decreases
>50%, indicating a requirement for these factors. Indeed, EF43
cells grow better in medium containing both EGF and insulin
but lacking serum than when grown in serum but lacking both
growth factors. In the presence of serum, expression of the Ha-
ras oncogene increases the growth rate of EF43 cells and reduces
their dependency upon EGF and insulin. However, the expres-
sion of p21ras appears to have rendered the EF43 cells more
dependent on some factors) present in serum. This factor(s)
seems to co-operate with ras expression to increase the growth
rate of the EF43 cells. In contrast, introduction of the v-mil
oncogene results in a slight reduction in growth rate in almost
all of the growth conditions.
Effect of oncogene expression upon morphology of the EF43
cell line
We investigated the morphology of the EF43 cell line, the
populations of virus-infected cells (EF43zip-m//-pop, EF43zip-
ros-pop, EF43zip-pop) and the clones generated either by
transfection (pSV2neo-EJ-transfected J series) or virus infection
(EF43myc) on plastic. At low cell density, no gross difference
in morphology is observed between the EF43 cell line and the
EF43 cell line containing ras, mil or myc when cultured on
plastic. At confluence, however, EF43 cells expressing the ras
oncogene reach a higher cell density and are metabolically more
active than the parental EF43 cells or EF43 cells expressing the
mil or myc oncogenes (data not shown).
Non-transformed mammary gland cells grown in collagen will
form three-dimensional tubular structures reminiscent of
mammary gland ducts (31,41). EF43 cells also display this
property (R.Ullrich, unpublished observations). Expression of
the ras, mil or myc oncogenes does not appreciably affect the
morphology of EF43 cells grown in collagen gels (data not
shown).
Effect of oncogene expression upon the anchorage-
independent growth and tumorigenicity in nude mice of the
EF43 cells
EF43 cells do not grow in an anchorage-independent manner
(Table I) and are not tumorigenic in nude mice. Introduction and
expression of the ras oncogene either by transfection (Jl, J2,
J3, J6 and J7) or by infection with a ras-containing virus
(EF43zip-rar-pop) confers upon them the ability to grow in an
anchorage-independent manner (Table I). Further, the EF43zip-
ras-pop cells rapidly induce tumors in nude mice and are also
tumorigenic in syngeneic animals (Table I). The transfected ras
gene is present in DNA extracted from a nude mouse tumor
arising from the J3 cell line (data not shown) indicating the
involvement of the ras oncogene in tumorigenesis. Introduction
of the \-mil oncogene into EF43 cells also confers upon them
the ability to grow in an anchorage-independent manner.
However, introduction and expression of \-myc does not result
in anchorage-independent growth of EF43 cells (Table I).
Table I. Effects of oncogenes introduced into
Cell line
EF43
Jl
J2
J3
J6
J7
EF43zip-pop
EF43zip-raj-pop
EF43zip-/m7-pop
EF43nryc
"1 x lo3 ceUs plated.
b l x 106 cells injected.
C2 X 103 cells injected.
Non- transfected
ras transfected
ras transfected
ras transfected
ras transfected
ras transfected
Infected
Infected
Infected
Infected
''Normal ductal outgrowth.
EF43 cells upon anchorage-independent growth,
Growth in
soft agar"
—ve
30%
13%
40%
12%
25%
—ve
22%
33%
—ve
Tumorigenicity in
nude mouse1'
0/2 after 7 weeks
1/2 after 6 weeks
2/2 after 2 weeks
2/2 after 3 weeks
2/2 after 2 weeks
2/2 after 3 weeks
NT
2/2 after 5 weeks
NT
NT
in vivo repopulation, and tumorigenicity
Repopulation of cleared
No. of mammary
outgrowths
0/16
0/16
0/16
0/16
NT
7/16d
0/16
0/16
4/16d
=Undiffercntiated morphology.
'Differentiated morphology.
'Animals observed for 54 days.
NT, not tested
fat pad0
No. of
tumors
15/16=
16/16=
16/16=
16/16=
0/16*
16/16=
9/16'
0/168
Latency
(days)
40
23
17
15
38
54
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Effect of oncogene expression upon the rcpopulation of the
cleared normal mammary fat pad
Normal ductal outgrowths can be observed when EF43 cells are
reimplanted into the cleared mammary fat pad (Figure 4A).
Reintroduction of EF43 cells infected with the empty ZTPneoSV(X)
virus, EF43zip-pop, also resulted in normal ductal repopulation
in 7 out of 16 (44%) mice (Table I). However, introduction and
expression of the Ha-ras oncogene both in the J series and in
the EF43zip-ras-pop totally abolishes this repopulation and instead
results in the rapid and efficient (100%) induction of tumors
(Table I). These tumors are histologically undifferentiated (Figure
4B,a). The introduction of the v-mil oncogene into EF43 cells
also leads to rapid tumor formation (Table I). However the tumors
derived from expression of the mil gene are histologically highly
differentiated (Figure 4B,b). Expression of the \-myc gene does
not interfere with the normal repopulation of the mammary gland
and these cells are not tumorigenic (Table I). When mice carrying
normal ductal outgrowths derived from the EF43 cells, the
EF43zip-pop cells or the EF43wyc cells received pituitary
isografts, the ductal outgrowths became alveolar, indicating a
normal differentiation response to pituitary hormones (Figure 4A,
inset).
mil, ras and myc in mammary cells
Discussion
Relatively little is known about the effects of oncogenes on
epithelial cells. Among the reasons for this are the difficulties
in obtaining and culturing primary epithelial cells, and the
difficulties involved in the introduction of oncogenes into these
cells which are generally refractile to gene transfer using
conventional techniques. The EF43 cell line divides indefinitely
in culture, differentiates in vivo and is readily transfectable and
infectable (30). Since the EF43 cell line is also non-tumorigenic,
it appears to represent the best available cell line for studying
the effects of cloned oncogenes upon differentiation parameters
of normal mammary epithelium, and the potential involvement
of such oncogenes in mammary tumorigenesis. We have intro-
duced the Ha-ras, \-mil and \-myc oncogenes independently into
this cell line and measured the effects of expression of these genes
upon a range of parameters.
Our results were not affected by the method of introduction
of the genes (transfection versus infection) or whether cell clones
or populations were analysed. The introduction and expression
of either the activated cellular or viral homolog of the Ha-ras
oncogene resulted in a tumorigenic conversion grossly
characterized by the ability to grow in an anchorage-independent
. »"•
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Fig. 4. (A) Mammary gland repopulated with EF43 cells at passage 18. The inset shows the histology of alveolar differentiation after pituitary isograft.
(B) Histology of tumors from reimplantation into the cleared mammary fat pads of BALB/c mice, (a) A poorly differentiated anaplastic tumor formed after
repopulation with the ras transfected clone Jl . The other rar-transfected cell clones and ras-infected cell population also formed anaplastic tumors of similar
histology (data not shown), (b) A well-differentiated adenocarcinoma formed by EF43 cells (EF43zip-m/7-population) infected with the v-mi/-cootaining
retro virus.
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manner and the formation of tumors in both nude and syngeneic
animals (Table I). Similar results have been obtained after
transfection of another mammary cell line, NMuMG, with the
Ha-ras oncogene (42). Since our interest is to determine the
effects of oncogenes potentially involved in mammary tumori-
genesis upon mammary gland cell growth and differentiation,
we chose to investigate parameters relevant to the mammary
gland.
Although expression of ras does not affect the morphology of
the EF43 cells either on plastic or within collagen matrices, the
growth rate of the EF43 cells is increased and their requirement
for EGF and insulin is reduced (Figure 3), implying that in vivo
such transformed cells are no longer responsive to growth factor
control of proliferation. However, expression of p21TO does not
reduce the requirement for serum, indicating that serum may
contain additional factors which co-operate with p21"" to
increase the overall growth rate of the EF43 cells. This factors)
is clearly not EGF or insulin. Recendy it has been shown that
a factors) present in serum may enhance the emergence of tumor
cells upon transfection of the Ha-ras oncogene into fibroblasts.
This factor does not appear to be a known growth factor (43).
Expression of Ha-ras prevents the in vivo parameter of repopu-
lation of the cleared mammary fat pad by the EF43 cells, and
instead results in the rapid formation of anaplastic tumors.
Anaplastic tumors are indicative of the later stages of mammary
tumor progression. The EF43 cells infected with retrovirus
lacking an oncogene are still able to participate in normal
repopulation of the cleared mammary fat pad, indicating that
expression of the Ha-ras oncogene disrupts normal differentiation.
The \-mil gene was originally isolated from the avian
carcinoma retrovirus MH2 which also carries a second oncogene,
v-myc (23). Deletion mutants of MH2 suggest that v-myc is the
primary oncogene of this virus whilst v-mil has auxilliary
oncogenic functions (44). In contrast, the murine homolog, v-raf,
found in the virus 3611-MSV, efficiendy transforms established
(20) as well as primary epithelial cells and established fibroblasts
(21). In view of the involvement of the mil/raf oncogene family
in carcinomas (20,21), we have investigated the effect of introduc-
tion and expression of the v-mil oncogene in EF43 cells. A mil-
related protein of 48 kd is detected in EF43 cells infected with
the v-m/^containing virus. This protein lacks the gag portion of
plQQgag-mU foun(j m MH2 virus-infected cells and has the same
mobility as a ra/-related protein (38). Expression of this protein
results in transformation of mammary epithelial cells. The \-mil
oncogene, like Ha-ras, induced anchorage-independent growth
in the EF43 cells (Table I) without any gross changes in cell
morphology. In contrast to ras expressing cells, this is not
accompanied by an increase in growth rate or an alleviation of
growth factor dependence since EGF and insulin are required
for growth (Figure 3). Expression of v-mil abolishes the ability
of the EF43 cells to repopulate the cleared mammary fat pad and
instead leads to the formation of differentiated adenocarcinomas
(Figure 4). Thus this truncated form of the mil gene has a
transforming activity in mammary epthelial cells and could play
a role in early stages of transformation of the mammary gland.
The myc gene has been implicated in both human (11,12) and
mouse (45) mammary carcinogenesis. Introduction and expression
of the v-myc by infection with the MMCV-neo retrovirus (25)
did not cause transformation of the EF43 cells, as judged by the
parameters we have tested. In accordance with the lack of
transformation, the ability of these cells to repopulate the cleared
mammary fat pad and respond to pituitary hormones was
unaffected (Table I). Recently it has been shown that myc has
no apparent effect on established fibroblasts of mammalian
(46,47) or avian (48) origin. It is possible that the levels of v-myc
expression may not be sufficient to affect the EF43 cells.
However, using a pan-wyc-specific antiserum we were only able
to detect v-myc, indicating a much higher expression than of
c-myc. Since EF43 cells grow indefinitely in culture, it is probable
that some immortalizing event has already occurred. This may
have rendered this cell line refractile to the effects of expression
of the myc oncogene, which is known to immortalize primary
cells (49). The v-mil oncogene has previously been regarded as
a potentiating oncogene, having no intrinsic transforming ability.
However, EF43 cells expressing v-mil are clearly tumorigenic
in vivo. If a myc-like event had already occurred in these cells,
v-mil may potentiate that effect resulting in neoplastic
characteristics.
Taken together, these data suggest that mammary tumorigenesis
proceeds by a number of stages, each of which is accompanied
by a concomitant loss of differentiation. Since the cell line that
we have chosen shows indefinite growth in vitro, it is not
'normal'; however, the EF43 cell line is still responsive to factors
that control mammary gland growth and differentiation. Intro-
duction and expression of a myc oncogene does not affect this
response. Thus although we cannot be certain whether indefinite
growth (immortalization) is a prerequisite for mammary tumori-
genesis, it is not sufficient per se to cause the development of
mammary neoplasia since it does not appreciably disrupt the
differentiative response of the mammary gland. The activation
of a cellular oncogene, functionally similar to mil/raf, in cells
that have already acquired the ability to proliferate indefinitely,
leads to a relatively differentiated tumor, the growth of which
is still dependent upon growth factors. Presumably the next
stage(s) in the progression towards overt mammary tumorigenesis
is the loss of growth control, a stage that can be partially achieved
by activating the ras oncogene. This would completely free the
mammary cell from growth control and contribute to its
invasiveness.
Our description of the molecular events that occur in mammary
tumorigenesis would accommodate earlier observations that, at
least in some mouse strains, the mammary tumor is rever-
sible—appearing during pregnancy when hormonal growth
stimulation is present, then regressing (growth factor responsive
tumor) and after three or four pregnancies becoming pregnancy
(and growth factor) independent (18). Rapid growth favors the
accumulation of mutations required for the progression to the
overt mammary tumor. In this light it is interesting that both int-1
and int-2 are putative embryonic growth factors (50,51) that are
inappropriately expressed in mammary tumors, and may con-
tribute to, but are probably not the primary cause of mammary
tumors.
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